BioSpace News Archive

P-BCMA-101 is a chimeric antigen receptor T cell (CAR-T) immunotherapy currently in a Phase 1 clinical trial as a treatment for relapsed and refractory multiple myeloma.

Shire plc announced the FDA awarded Orphan Drug Designation to Shire’s gene therapy candidate SHP654 (also designated as BAX 888).

President Trump’s designation of the opioid crisis as a public health emergency takes an important step toward solving a problem that impacts people of all ages and ethnic groups throughout the nation.

Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

China Resources Pharmaceutical filed with the Hong Kong exchange to raise $368.5 million in an investment fund.

To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 2193619.

Irish based Arran Chemical Company has responded to client demand for provision of fine chemicals, pharmaceutical intermediates and advanced building blocks by implementation of its ADAPT (Arran Deploys Advanced Production Technologies) strategy through a multi-million Euro investment and application of its selectAZyme technology.

The exercise of the greenshoe option also marks the end of the stabilization period in relation to the initial U.S. public offering.

The company announced its financial results for the six-months ended June 30, 2017, as approved by the Company’s Board of Directors on October 27, 2017.

Four out of six evaluable HRAS mutant HNSCC patients enrolled in the study achieved a confirmed partial response.